Biogen and AbbVie withdraw Zinbryta from market

March 02, 2018
Biogen and AbbVie announced the voluntary worldwide withdrawal of Zinbryta for relapsing multiple sclerosis following reports of inflammatory encephalitis and meningoencephalitis.

Biogen will continue to work collaboratively with regulatory authorities in the withdrawal from market and with healthcare providers worldwide in their support of Zinbryta patients. Patients currently treated with Zinbryta should contact their healthcare provider if they have any questions or concerns.

MS Focus Lending Library


Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more

Study uncovers potential risks of common MS treatment


Study finds an increased risk of events such as stroke, migraine, and depression, and abnormalities in the blood with taking beta interferon for MS.
Learn more

Floodlight Open now enrolling in the U.S.

June 18, 2018

Floodlight Open is a new global study to collect and monitor anonymized patient data to gain a better understanding of MS disease progression
Learn more